Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

CSTZFN

Sigma-Aldrich

CompoZr® Custom Zinc Finger Nuclease (ZFN)

ZFN plasmid and mRNA

Sign Into View Organizational & Contract Pricing

UNSPSC Code:
12352200

Quality Level

product line

CompoZr®

shipped in

dry ice

storage temp.

−70°C

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Zinc Finger Nucleases (ZFNs) are a class of engineered DNA-binding proteins that facilitate targeted editing of the genome by creating double-strand breaks in DNA at user-specified locations. Double-strand breaks are important for site-specific mutagenesis in that they stimulate the cell′s natural DNA-repair processes, namely homologous recombination and Non-Homologous End Joining (NHEJ). By implementing established, field-proven methods, these processes can be harnessed to generate precisely targeted genomic edits, resulting in cell lines with precise and heritable gene deletions, integrations or modifications.

Application

Functional Genomics/Target Validation
  • Creation of gene knockouts in multiple cell lines
  • Complete knockout of genes not amenable to RNAi
Cell-based Screening
  • Creation of knock-in cell lines with promoters, fusion tags or reporters integrated into endogenous genes
Cell Line Optimization
  • Creation of cell lines that produce higher yields of proteins or antibodies
The CompoZr Custom ZFN service can be used to target genes from a variety of organisms. Validation of the custom ZFNs is completed in a proxy cell line for human, mouse, rat and hamster (CHO) projects. In this assay, the candidate ZFNs are delivered to the proxy cell line and activity is identified and measured. Activity is measured by amplifying over the ZFN target site and then using a nuclease mismatch enzyme to cut DNA strands that have been modified. ZFN efficiency can be measured based on the densitometry results of this assay. CompoZr Custom ZFN Projects for human, mouse, rat, and hamster (CHO) will have a production timeline of 10 weeks after the ZFN design is approved.

Features and Benefits

  • Rapid design, assembly, and validation of a ZFN pair targeting your gene of interest
  • Rapid and permanent disruption of, or integration into, any genomic loci
  • Mutations made are permanent and heritable
  • Works in a variety of mammalian somatic cell types
  • Edits induced through a single transfection experiment
  • Knockout or knock-in cell lines in as little as two months
  • Single or biallelic edits occur in 1-20% of clone population
  • No antibiotic selection required for screening

Components

  • Best Performing ZFN Pair
  • 10 Aliquots of Ready-to-Deliver ZFN Pair in mRNA form
  • ZFN Pair in Plasmid Form
  • Forward and Reverse Primers that allow for determination of rate of mutation and for screening of individual clones
  • Positive Control DNA
  • Used to determine a baseline cutting efficiency

Other Notes

To have a ZFN made targeting your gene of interest, please inquire about our
Custom ZFN Service offering HERE

Legal Information

All Zinc Finger Nucleases are sold under license from Sangamo Biosciences. For a copy of the Label License provided with purchase of CompoZr ZFNs, please visit the ZFN Label License page.
CompoZr is a registered trademark of Merck KGaA, Darmstadt, Germany

related product

Product No.
Description
Pricing

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

新产品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

  1. Which document(s) contains shelf-life or expiration date information for a given product?

    If available for a given product, the recommended re-test date or the expiration date can be found on the Certificate of Analysis.

  2. How do I get lot-specific information or a Certificate of Analysis?

    The lot specific COA document can be found by entering the lot number above under the "Documents" section.

  3. How do I find price and availability?

    There are several ways to find pricing and availability for our products. Once you log onto our website, you will find the price and availability displayed on the product detail page. You can contact any of our Customer Sales and Service offices to receive a quote.  USA customers:  1-800-325-3010 or view local office numbers.

  4. What is the Department of Transportation shipping information for this product?

    Transportation information can be found in Section 14 of the product's (M)SDS.To access the shipping information for this material, use the link on the product detail page for the product. 

  5. What is a Zinc Finger Nuclease (ZFN)?

    A ZFN is a hybrid molecule that couples the DNA binding domain of a zinc-finger protein with the DNA-cleaving nuclease domain of the restriction endonuclease FokI. The DNA binding motif specified by the zinc fingers directs the ZFN to a specific (targeted) locus in the genome.

  6. Why are these sometimes referred to as ZFN pairs?

    A pair of ZFNs is required to cleave double-stranded DNA. This is a requirement of the FokI nuclease. FokI must dimerize to achieve a double strand break in the DNA. You will be provided with a pair of ZFNs for your target site that has been validated to cut at the endogenous chromosomal locus in a proxy cell line.

  7. What specificity should be expected from a ZFN?

    Due to the dimerization requirement of the FokI endonuclease, a pair of ZFNs is required to cause a double strand break. This strategy requires two different ZFNs to bind at the target site. Each ZFN recognizes a different 12-18 base pair target sequence, and these target sequences must be separated by 4-7 base pairs to allow formation of the catalytically active FokI dimer. These positional constraints drive a very high degree of specificity.

  8. Will a ZFN knockout a gene in my cell line?

    Yes. ZFNs for gene knockout typically target within the ORF of coding exons. The ZFN that is delivered to you for gene knockout will cause a targeted double strand breakage (DSB) in the genome of your cells. After the DNA is cut by the ZFN, the cell repairs the breakage by the natural process of non-homologous end joining (NHEJ). This is an imperfect repair process that usually results in the loss or gain of genetic information (typically tens of base pairs) at the site of the DSB. Due to the mutations caused by ZFN-mediated NHEJ, 1-20% of resulting clones are expected to have both copies of the target gene knocked out.

  9. Will a ZFN insert a gene into my cell line?

    Yes. To achieve targeted gene integration you must co-transfect your ZFN with a repair template, consisting of the gene to be inserted flanked by genomic sequence engineered to match (i.e., be homologous to) the sequence surrounding the intended ZFN cut site. After your ZFN cuts at the site specified by its sequence, the natural mechanism of homology dependent repair (HDR) takes over. The cell will recognize the homologous sequence in the repair template and insert the exogenous gene at the site of ZFN cleavage.

  10. What is the best way to deliver the ZFN and the repair template into the cells?

    The ZFN itself can be delivered as a plasmid or it can be transcribed into an mRNA transcript for delivery. We have found both plasmid and mRNA to be effective depending on cell type and, therefore, provide customers with ZFNs in both plasmid and mRNA form to test in their own cell lines. Repair templates are typically delivered into the cell as linear DNA. Regardless of form, mRNA, DNA, or plasmid, we have found that the use of nucleofection or electroporation generally produce the highest DNA cleavage efficiencies. Due to this increase in efficiency, we recommend using an electroporation or nucleofection delivery method if possible. Lipid-based transfection also works in many cases, but may result in lower efficiencies.

  11. How is the binding specificity of the ZFN tested?

    The binding specificity of the zinc finger modules in the Sangamo archive have previously been characterized by a number of in-vitro methods (ELISA among others).

  12. How has the cleavage ability of my ZFN been tested?

    To test the cleavage ability of the ZFNs we use a mismatch-specific nuclease assay. In this assay, PCR primers are used to amplify across the ZFN cleavage site in genomic DNA extracted from ZFN-treated cells. The resulting PCR products, which are now a mixture of wild type and mutated amplicons, are then denatured and re-annealed. When wild type and mutant alleles of the PCR products re-anneal with each other a mismatch occurs. The fragments are then exposed to a mismatch-specific nuclease and the digested reaction is run on a gel to look for smaller migrating cleavage products that indicate cleaved mismatches. The smaller migrating cleavage products reflect the frequency of mutated alleles and are a measure of in vivo ZFN efficacy. Quantitation of the released fragments allows a calculation of the percentage of mutated genes in the population.

  13. In which cell lines/organisms do the ZFNs work?

    Sigma has a standard offering of ZFNs for Human, Mouse, and Rat. We expect the ZFN technology to work in most organisms. For instance, ZFNs have recently been shown to produce site-specific gene knockouts in Zebrafi sh (Doyon et al., Nature Biotechnology., May 25, 2008). The ZFNs for this particular application were tested in a yeast proxy system that accurately reflects ZFN activity in many other cell types.

  14. I have a cell line I created by using a ZFN to knockout a gene. I would like to knockout a second gene in this cell line. Is this possible?

    Yes, this is definitely a possibility. It has been shown that at least 3 different genes could be successively knocked out of the genome in the same cell line.

  15. Can every gene be targeted by a ZFN?

    Yes. Using our current library of 2-finger zinc finger modules, we believe we can produce a working ZFN for about every 200 bp on average, making genome wide coverage feasible. We plan to continue updating our library of zinc finger modules to increase the genomic coverage.

  16. Should I expect off-target effects from my ZFN?

    The ZFN reagents that we provide are unlikely to cause significant offtarget effects. The proprietary algorithm that Sigma uses to design the candidate ZFNs targets only sites that are unique within the genome. This, as well as the use of specially engineered obligate heterodimer FokI cleavage domains (Miller et al., Nature Biotechnology, July 25, 2007), helps guard against off-target effects for the ZFN you receive.

  17. My cell line is very hard to transfect. Can I still use ZFNs?

    Efficiency of delivery is very important. We have had great success with viral delivery of ZFNs, including AdV, AAV and lentivirus. If you have a viral delivery system available, then we can give guidance on how to apply it to the use of ZFNs.

  18. Do the ZFNs remain in the cells after causing desired mutations?

    No. The ZFNs are only expressed transiently but the genetic alteration is permanent. The transient nature of ZFNs also reduces the possibility of off-target effects.

  19. When using Product CSTZFN, CompoZr® Custom Zinc Finger Nuclease, ZFN,do I need to use a selection marker for Targeted Gene Integration?

    In many cases the efficiency of Targeted Gene Integration is >1% - even without selection. So selection markers are often not necessary. However, in certain circumstances, selection might be useful to have, e.g., when working with poorly transfectable cells.

  20. Can Zinc Finger Nucleases be synthesized to a specific mitochondrial DNA sequence?

    This is target dependent, however the simple answer is yes- as long as sequence content is fairly diverse with some GC content.  There is already literature for targeting of mtDNAs with ZFNs.

  21. Can Zinc Finger Nucleases be cloned in an inducible promoter? 

    Yes, though we don't have any examples or data around this.  It is effectively a typical expression cassette so there should not be a problem.  However, there are several potential outcomes.  If a pair of catalytically active ZFN expression cassettes are stably integrated into a genome, any "leaky" expression could result in premature gene editing.  Additionally, we should also consider the fact that we have no control over the type of modification incurred at the ZFN target site (assuming no donor is introduced).  The outcomes might include small insertions and deletions resulting in frameshift (like we want) or it could result in an in-frame modification that may not necessarily yield functional gene knockout.

  22. My question is not addressed here, how can I contact Technical Service for assistance?

    Ask a Scientist here.

Yoshihiro Inami et al.
The Journal of cell biology, 193(2), 275-284 (2011-04-13)
Suppression of autophagy is always accompanied by marked accumulation of p62, a selective autophagy substrate. Because p62 interacts with the Nrf2-binding site on Keap1, which is a Cullin 3-based ubiquitin ligase adapter protein, autophagy deficiency causes competitive inhibition of the
Chun Cheng Andy Chen et al.
Physiological genomics, 45(3), 110-118 (2012-12-20)
The present study employed a zinc-finger nuclease strategy to create heterozygous knockout (KO) rats for the transforming growth factor-β1 (Tgfb1) gene on the Dahl SS/Jr genetic background (TGF-β1(+/-) Dahl S). Intercrossing TGF-β1(+/-) rats did not produce any homozygous KO rats
To Uyen Do et al.
Mutation research, 740(1-2), 34-42 (2013-01-08)
Radiation treatment or chemotherapy has been linked with a higher risk of secondary cancers such as therapy related Acute Myeloid Leukemia (tAML). Several of these cancers have been shown to be correlated to the introduction of double stranded breaks (DSB)
A Tanaka et al.
Leukemia, 27(8), 1621-1627 (2013-02-16)
Human T-cell leukemia virus type 1 (HTLV-1), which causes adult T-cell leukemia (ATL) in humans, establishes a life-long latent infection. Current therapies are not very effective against HTLV-1-associated disorders. A novel therapeutic approach may help to combat HTLV-1 infection. A
Bettina Schmid et al.
Proceedings of the National Academy of Sciences of the United States of America, 110(13), 4986-4991 (2013-03-05)
Mutations in the Tar DNA binding protein of 43 kDa (TDP-43; TARDBP) are associated with amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43(+) inclusions (FTLD-TDP). To determine the physiological function of TDP-43, we knocked out zebrafish Tardbp and

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service